Abstract Submission is Open
Submit your abstract for ARVO 2019 by November 30.
IOVS Special issue
View a special issue of IOVS journal on Dry Age-Related Macular DegenerationGlobal mentorship
Global mentors and mentees talk relationship buildingTraveling to ARVO 2019
Helpful tips for your trip to VancouverJoin us in Vancouver
Register early for ARVO 2019 and saveARVO members among 2018 Champalimaud Vision Award winners
Seven scientists were recognized for their extraordinary scientific advances which led to the successful treatment of a genetic cause of childhood blindness, a version of Leber Congenital Amaurosis, and demonstrated the potential for future developments in gene therapy to cure other inherited diseases.
Publications grant
Apply for ARVO’s Publications Grant, available to authors who need funding assistance to publish in one of our three journals
Apply for the Women's Leadership Development Program
We are seeking mentor and mentee applicants for the 2019 - 2020 program year. The program provides emerging women leaders within the ARVO membership a highly interactive, year-long learning experience focused on developing leadership skills and facilitating leadership opportunities and networking. Deadline to apply is Oct. 31.
Upcoming Events
Abstract submission is open
Note that the deadline to submit an abstract for the ARVO 2019 Annual Meeting in Vancouver is Nov. 30, 2018.
ARVO key dates and deadlines
View a monthly listing of key dates and deadlines for the Eye and Vision Science Community
Plan your stay at ARVO 2019
Book your hotel room now and get the best selection for ARVO 2019 in Vancouver, Canada, April 28 - May 2
Latest news
Visit our Press Room to see the latest eye and vision research news and view ARVO press releases.
Telling the story of OCT
Optical coherence tomography (OCT) is a technology invented by ARVO members that helps preserve patients' sight, saves taxpayers billions of dollars and enables further discoveries in science and medicine. See how ARVO has shared the impact of OCT with vision scientists, patients, and policymakers.
